Biomarkers in Pulmonary Infections

Pedro Póvoa*, Luís Coelho, Lieuwe J. Bos

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Pneumonia, either community acquired or hospital acquired, is the most frequent severe infection. Despite all new tools and developments, pneumonia is difficult to diagnose clinically, resulting from the lack of a "gold standard" method of diagnosis. This uncertainty is at least in part responsible for the overuse and misuse of antibiotics in the community and in the hospital, and this practice is probably a main drive for antibiotic resistance. Biomarkers may improve the clinical evaluation of a patient with a clinical suspicion of pneumonia. Among all the potential biomarkers, C-reactive protein and procalcitonin are the most extensively studied and used in clinical practice, and their role in triage, diagnosis, risk stratification, monitoring clinical course, and antibiotic stewardship has been extensively assessed. Both biomarkers showed that their use as an additional tool could be useful in the management of pneumonia. More recently "omics" technologies began to be used as new approaches in pneumonia. These promising technologies could in the near future improve the management of pneumonia.

OriginalsprogEngelsk
TidsskriftClinical Pulmonary Medicine
Vol/bind26
Udgave nummer4
Sider (fra-til)118-125
ISSN1068-0640
DOI
StatusUdgivet - 1. jul. 2019

Fingeraftryk

Lung
Community Hospital
Microbial Drug Resistance
Uncertainty

Citer dette

Póvoa, Pedro ; Coelho, Luís ; Bos, Lieuwe J. / Biomarkers in Pulmonary Infections. I: Clinical Pulmonary Medicine. 2019 ; Bind 26, Nr. 4. s. 118-125.
@article{301965ce9c8949dc905689011fd744de,
title = "Biomarkers in Pulmonary Infections",
abstract = "Pneumonia, either community acquired or hospital acquired, is the most frequent severe infection. Despite all new tools and developments, pneumonia is difficult to diagnose clinically, resulting from the lack of a {"}gold standard{"} method of diagnosis. This uncertainty is at least in part responsible for the overuse and misuse of antibiotics in the community and in the hospital, and this practice is probably a main drive for antibiotic resistance. Biomarkers may improve the clinical evaluation of a patient with a clinical suspicion of pneumonia. Among all the potential biomarkers, C-reactive protein and procalcitonin are the most extensively studied and used in clinical practice, and their role in triage, diagnosis, risk stratification, monitoring clinical course, and antibiotic stewardship has been extensively assessed. Both biomarkers showed that their use as an additional tool could be useful in the management of pneumonia. More recently {"}omics{"} technologies began to be used as new approaches in pneumonia. These promising technologies could in the near future improve the management of pneumonia.",
keywords = "biomarkers, C-reactive protein, community-acquired pneumonia, pneumonia, procalcitonin, ventilator-associated pneumonia",
author = "Pedro P{\'o}voa and Lu{\'i}s Coelho and Bos, {Lieuwe J.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/CPM.0000000000000322",
language = "English",
volume = "26",
pages = "118--125",
journal = "Clinical Pulmonary Medicine",
issn = "1068-0640",
publisher = "Lippincott Williams & Wilkins",
number = "4",

}

Póvoa, P, Coelho, L & Bos, LJ 2019, 'Biomarkers in Pulmonary Infections', Clinical Pulmonary Medicine, bind 26, nr. 4, s. 118-125. https://doi.org/10.1097/CPM.0000000000000322

Biomarkers in Pulmonary Infections. / Póvoa, Pedro; Coelho, Luís; Bos, Lieuwe J.

I: Clinical Pulmonary Medicine, Bind 26, Nr. 4, 01.07.2019, s. 118-125.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Biomarkers in Pulmonary Infections

AU - Póvoa, Pedro

AU - Coelho, Luís

AU - Bos, Lieuwe J.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Pneumonia, either community acquired or hospital acquired, is the most frequent severe infection. Despite all new tools and developments, pneumonia is difficult to diagnose clinically, resulting from the lack of a "gold standard" method of diagnosis. This uncertainty is at least in part responsible for the overuse and misuse of antibiotics in the community and in the hospital, and this practice is probably a main drive for antibiotic resistance. Biomarkers may improve the clinical evaluation of a patient with a clinical suspicion of pneumonia. Among all the potential biomarkers, C-reactive protein and procalcitonin are the most extensively studied and used in clinical practice, and their role in triage, diagnosis, risk stratification, monitoring clinical course, and antibiotic stewardship has been extensively assessed. Both biomarkers showed that their use as an additional tool could be useful in the management of pneumonia. More recently "omics" technologies began to be used as new approaches in pneumonia. These promising technologies could in the near future improve the management of pneumonia.

AB - Pneumonia, either community acquired or hospital acquired, is the most frequent severe infection. Despite all new tools and developments, pneumonia is difficult to diagnose clinically, resulting from the lack of a "gold standard" method of diagnosis. This uncertainty is at least in part responsible for the overuse and misuse of antibiotics in the community and in the hospital, and this practice is probably a main drive for antibiotic resistance. Biomarkers may improve the clinical evaluation of a patient with a clinical suspicion of pneumonia. Among all the potential biomarkers, C-reactive protein and procalcitonin are the most extensively studied and used in clinical practice, and their role in triage, diagnosis, risk stratification, monitoring clinical course, and antibiotic stewardship has been extensively assessed. Both biomarkers showed that their use as an additional tool could be useful in the management of pneumonia. More recently "omics" technologies began to be used as new approaches in pneumonia. These promising technologies could in the near future improve the management of pneumonia.

KW - biomarkers

KW - C-reactive protein

KW - community-acquired pneumonia

KW - pneumonia

KW - procalcitonin

KW - ventilator-associated pneumonia

U2 - 10.1097/CPM.0000000000000322

DO - 10.1097/CPM.0000000000000322

M3 - Journal article

VL - 26

SP - 118

EP - 125

JO - Clinical Pulmonary Medicine

JF - Clinical Pulmonary Medicine

SN - 1068-0640

IS - 4

ER -